Company news

GeneDx Holdings Corp. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

GeneDx to Present New Data on Urine Mitochondrial DNA Testing at the 2023 United Mitochondrial Disease Foundation’s Mitochondrial Medicine Symposium

June 27, 2023

GeneDx Announces New Tool to Help Harness Human Pangenome Diversity for Clinical Interpretation of Variants

June 25, 2023

GeneDx Commends the States of Arizona and Florida for Adding Rapid Whole Genome Sequencing (rWGS) as a Covered Benefit for Medicaid Pediatric Patients

June 19, 2023

GeneDx to Participate in Upcoming Investor Conferences in June

May 23, 2023

GeneDx to Participate in World Orphan Drug Congress Keynote and Panel Presentations

May 22, 2023

GeneDx Regains Compliance with Nasdaq Minimum Bid Price Requirement

May 21, 2023

GeneDx Reports First Quarter 2023 Financial Results and Business Highlights

May 8, 2023

GeneDx Adds Buccal Swab as Non-Invasive Whole Genome Sequencing Sample Collection Option

May 3, 2023

GeneDx Announces Clarification Regarding CUSIP Number for Public Warrant Holders

May 2, 2023

GeneDx Announces Reverse Stock Split

April 27, 2023

GeneDx to Report First Quarter 2023 Financial Results on Tuesday, May 9, 2023

April 17, 2023

GeneDx Appoints Devin K. Schaffer, J.D., M.B.A, as General Counsel

April 2, 2023

GeneDx Announces Progress on GUARDIAN Study and Promise of Early Genomic Testing to End Rare Disease “Diagnostic Odyssey”

March 19, 2023

GeneDx Presents New Data at ACMG Demonstrating the Benefits of Exome Sequencing Over Chromosomal Microarray

March 15, 2023

GeneDx Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

March 13, 2023

GeneDx to Participate in the Cowen 43rd Annual Healthcare Conference

February 28, 2023

GeneDx honors Rare Disease Day and announces presentations and research at the 2023 American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting

February 27, 2023

GeneDx to Report Fourth Quarter and Full Year 2022 Financial Results on Tuesday, March 14th, 2023

February 20, 2023

GeneDx Rare Disease Data Demonstrates Utility in Drug Candidate Identification for Common Diseases

February 15, 2023

GeneDx Announces Closing of Underwritten Public Offering and Concurrent Registered Direct Offering

January 30, 2023

GeneDx Makes Significant Industry-Wide Contributions to New Disease Gene Discovery

January 29, 2023

GeneDx Holdings Announces Pricing Of A $150 Million Underwritten Public Offering Of Class A Common Stock And Concurrent Registered Direct Offering

January 26, 2023

GeneDx Announces Proposed Underwritten Public Offering of Class a Common Stock and Concurrent Registered Direct Offering

January 25, 2023

Sema4 Announces Name Change to GeneDx and Provides Preliminary 2022 Financial Results and 2023 Guidance

January 8, 2023

Sema4|GeneDx to Participate in the 41st Annual J.P. Morgan Healthcare Conference

December 29, 2022

New Research from Sema4|GeneDx Highlights the Importance of Rapid Exome Sequencing for Diagnosing Mitochondrial Diseases in the NICU

December 4, 2022

Sema4 Reports Third Quarter 2022 Financial Results and New Strategic Direction

November 13, 2022

Sema4 to Report Third Quarter 2022 Financial Results on Monday, November 14th, 2022

November 3, 2022

Sema4|GeneDx Commends New Evidence-Based Guidelines from the National Society of Genetic Counselors Recommending Exome Sequencing as a First-Tier Genetic Test for Unexplained Epilepsies

October 30, 2022

Sema4|GeneDx Announces Results from Phase 1 of SeqFirst Study, Demonstrating Broad Utility of Rapid Whole Genome Sequencing for Critically Ill Newborns

October 26, 2022

Sema4|GeneDx collaborates on new research demonstrating genome and exome sequencing deliver more diagnostic certainty than multi-gene panels

October 25, 2022

Sema4|GeneDx To Provide Whole Genome Sequencing and Interpretation Services for Landmark Genomic Newborn Screening Study

October 4, 2022

Sema4 Appoints Healthcare and Diagnostics Industry Veteran Kevin Feeley as Chief Financial Officer

August 25, 2022

Sema4 Announces Continued Restructuring, Business Highlights, and Reports Second Quarter 2022 Financial Results

August 14, 2022

Sema4 Announces Changes to its Research & Development Leadership

August 14, 2022

Sema4 to Report Second Quarter 2022 Financial Results on Monday, August 15, 2022

July 25, 2022

Sema4 Announces Chief Financial Officer Transition Plan

June 13, 2022

Avera Health and Sema4 Announce Data-driven Study to Advance Cancer Treatment Across the Avera Service Area

May 31, 2022

Sema4 to Participate at Two Investor Conferences in June 2022

May 25, 2022

Sema4 Reports First Quarter 2022 Financial Results and Business Highlights

May 11, 2022

Sema4 Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 3, 2022

Sema4 Announces the Completion of the GeneDx Acquisition and a Streamlined Leadership Structure to Accelerate Growth of its Diagnostic and Clinical Data Platforms

May 1, 2022

Sema4 to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022

April 25, 2022

Sema4 Achieves HITRUST CSF Certification

April 5, 2022

Sema4 and Mount Sinai Use Integrative Network Analysis to Identify Potential New Lung Cancer Therapy

April 4, 2022

Sema4 Announces Nationwide Expansion of Disparity Study to Deliver Precision Oncology Care to Underserved Communities

March 15, 2022

Sema4 Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights

March 13, 2022

Sema4 Named to Fast Company’s Annual List of the World’s Most Innovative Companies for 2022

March 7, 2022

Sema4 to Report Fourth Quarter and Full Year 2021 Financial Results and Participate in Investor Conferences in March 2022

February 21, 2022

Sema4 and BioSymetrics Partner on Data-Driven Drug Discovery to Advance Precision Medicine

February 21, 2022

← Newer news releases · Older news releases →

Calls

The 5 newest of 20 calls. Every call is listed under its year.

Decks

The 5 newest of 36 decks. Every deck is listed under its year.